These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32542108)

  • 1. Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies.
    Dickopf S; Georges GJ; Brinkmann U
    Comput Struct Biotechnol J; 2020; 18():1221-1227. PubMed ID: 32542108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
    Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
    Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties.
    Nyesiga B; Levin M; Säll A; Rosén A; Jansson K; Fritzell S; Hägerbrand K; Weilguny D; von Schantz L
    MAbs; 2024; 16(1):2330113. PubMed ID: 38527972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies.
    Mohan N; Ayinde S; Peng H; Dutta S; Shen Y; Falkowski VM; Biel TG; Ju T; Wu WJ
    Front Immunol; 2024; 15():1376096. PubMed ID: 38863707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The making of bispecific antibodies.
    Brinkmann U; Kontermann RE
    MAbs; 2017; 9(2):182-212. PubMed ID: 28071970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
    Riffard C; Teillaud JL
    Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.
    Harwood SL; Alvarez-Cienfuegos A; Nuñez-Prado N; Compte M; Hernández-Pérez S; Merino N; Bonet J; Navarro R; Van Bergen En Henegouwen PMP; Lykkemark S; Mikkelsen K; Mølgaard K; Jabs F; Sanz L; Blanco FJ; Roda-Navarro P; Alvarez-Vallina L
    Oncoimmunology; 2017; 7(1):e1377874. PubMed ID: 29296540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies for immune cell retargeting against cancer.
    Chen RP; Shinoda K; Rampuria P; Jin F; Bartholomew T; Zhao C; Yang F; Chaparro-Riggers J
    Expert Opin Biol Ther; 2022 Aug; 22(8):965-982. PubMed ID: 35485219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.
    Loh HP; Mahfut FB; Chen SW; Huang Y; Huo J; Zhang W; Lam KP; Xu S; Yang Y
    MAbs; 2023; 15(1):2231129. PubMed ID: 37403264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the bispecific antibody IgG subclass on T cell redirection.
    Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
    MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity.
    Shi SY; Lu YW; Liu Z; Stevens J; Murawsky CM; Wilson V; Hu Z; Richards WG; Michaels ML; Zhang J; Yan W; Li Y
    J Biol Chem; 2018 Apr; 293(16):5909-5919. PubMed ID: 29483191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
    Yang F; Wen W; Qin W
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The manufacturing considerations of bispecific antibodies.
    Underwood DJ; Bettencourt J; Jawad Z
    Expert Opin Biol Ther; 2022 Aug; 22(8):1043-1065. PubMed ID: 35771976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward Drug-Like Multispecific Antibodies by Design.
    Sawant MS; Streu CN; Wu L; Tessier PM
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma.
    O'Connell RP; Liaw K; Wellhausen N; Chuckran CA; Bhojnagarwala PS; Bordoloi D; Park D; Shupin N; Kulp D; June CH; Weiner D
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38834201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.
    Liu H; Saxena A; Sidhu SS; Wu D
    Front Immunol; 2017; 8():38. PubMed ID: 28184223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
    Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.